Turlough O'HAre

Turlough O'HAre

Auto-generated profile, based on publicly available information

Turlough O'HAre

Department of Anesthesia, McMaster University, Hamilton, ON, Canada

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Journal of Cardiothoracic and Vascular Anesthesia
Verified
Journal Article
Closed access
HSHarsha Shanthanna
Harsha Shanthanna
PMPeter Moisuik
Peter Moisuik
TOTurlough O’hAre
Turlough O’hAre
SSSadeesh K. Srinathan
Sadeesh K. Srinathan
CFChristian Finley
Christian Finley
PSPeter Slinger
Peter Slinger

1 February 2020 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
HSHarsha Shanthanna
Harsha Shanthanna
ATAlparslan Turan
Alparslan Turan
JVJessica Vincent
Jessica Vincent
RSRemie Saab
Remie Saab
YSYaron Shargall
Yaron Shargall
PDPhilip J Devereaux
Philip J Devereaux
Purpose: We conducted a feasibility 2× 2 factorial trial comparing N-methyl-D-aspartate (NMDA) antagonists (intravenous ketamine and oral memantine) versus placebo and intravenous steroids versus placebo, in patients having elective video-assisted thoracic surgery lobectomies, at St. Joseph’s Hamilton, Canada, and Cleveland Clinic, Cleveland, USA. Our feasibility objectives were: 1) recruitment rate/week; 2) recruitment of ≥ 90% of eligible patients; and 3) > 90% follow-up. Secondary objectives were incidence and intensity of persistent post-surgical pain (PPSP) and other clinical and safety outcomes. Methods: Using computerized randomization, patients were allocated to one of four groups: NMDA active with steroid placebo; NMDA placebo with steroid active; both NMDA and steroid active; both NMDA and steroid placebo. Patients, health providers, and data analysts were blinded to allocation. Patients were followed for 3 months after randomization. Results: The trial was initiated in May 2017 at Hamilton and, after subsequent regulatory and ethics approval, in April 2018 at Cleveland. The trial had to be stopped after only 1 month of recruitment in Cleveland because the packaged study medications (memantine) expired and we were unable to procure the dosage required. Among 41 eligible patients, 27 (66%) were randomized. The recruitment rate/week was 0.63, 95% confidence interval (CI): 0.47– 0.79 in Hamilton; and 1, 95% CI: 0.83– 1.17 in Cleveland. Follow-up was complete for all 24 patients (100%) in Hamilton, and 3 of 4 patients in Cleveland. In total, only 4 patients (15%), and 2 patients (7%) had persistent pain at rest and with movement, respectively. There were no significant differences between groups for other outcomes. Conclusion: The trial had to be stopped prematurely due to non-availability of study medications. Trial feasibility objectives of recruiting 90% of eligible patients and recruiting at least one patient/week per site were not met. Consideration for protocol changes will be necessary for the full trial. Trial Registration: NCT02950233.